Gan & Lee Pharmaceuticals' GZR18 injection, a bi-weekly GLP-1 receptor agonist, showed a 17.29% weight reduction after 30 weeks in a Phase IIb study.

Nuvalent reported the launch of HEROEX-1, its Phase 1a/1b clinical study testing the new HER2-selective inhibitor NVL-330.

Johnson & Johnson is requesting U.S. FDA approval for SPRAVATO® (esketamine) as the sole treatment for adults with treatment-resistant depression.

This study assessed the safety, tolerability, and pharmacokinetics of their leading lipidated IL-22 candidate, CK-0045.

The European Medicines Agency has approved Bristol Myers Squibb's application to use Opdivo (nivolumab) and Yervoy (ipilimumab) as initial treatments.

NGM Bio Secures $122 Million in Series A to Launch Primary Sclerosing Cholangitis Trial and Support Phase 2 Hyperemesis Gravidarum Study.

Immutep Gets Approval for Phase I Trial of Novel LAG-3 Agonist Antibody Targeting Autoimmune Disorders.

Biotheryx Initiates Phase 1 Trial, Administers Initial Dose of BTX-9341, a Novel Dual Action CDK4/6 Degrader, Alone and with Other Treatments.

Atara Biotherapeutics announced that the FDA has granted priority review for its Tab-cel® application to treat EBV+ PTLD.

4DMT reports encouraging Phase 2 PRISM interim outcomes for Intravitreal 4D-150 in diverse wet AMD patients, confirming positive safety and strong clinical efficacy.

Bayer reveals promising primary results for NUBEQA® (darolutamide) from a Phase III study in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Genentech Reports Promising Phase I Outcomes for Oral GLP-1 Receptor Agonist CT-996 in Obesity Treatment.